| abstract |
The invention relates to the use of folates for producing a pharmaceutical preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers C-reactive protein (CRP) and serum amyloid A protein (SAA). Clinical fields of application are all anomalies of the CRP and SAA level. The invention also relates to pharmaceutical preparations for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the CRP and SAA level, said preparations being characterised in that they contain at least one compound as an active ingredient, selected from the group comprising pteroic acid monoglutamate (folic acid), dihydrofolic acid, 5-formyltetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, 5,10-methenyltetrahydrofolic acid, 10-formyltetrahydrofolic acid or tetrahydrofolic acid, the polyglutamates thereof, the optical isomers thereof, especially the optical, purely natural isomers thereof but also mixtures of optical isomers, especially racemic mixtures, the pharmaceutically acceptable salts thereof, and pharmaceutically acceptable active ingredients and auxiliary agents. |